Heartflow, Inc. (NASDAQ:HTFL) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Heartflow, Inc. (NASDAQ:HTFL) has received a consensus rating of "Moderate Buy" from analysts, with one hold and four buy recommendations.
• The average twelve-month price target for Heartflow among brokerages is $35.80, with several analysts setting targets between $35.00 and $38.00.
• Heartflow's stock opened at $31.50, representing a 12-month range between $26.56 and $36.68.

Shares of Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $35.80.

Several analysts have recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Heartflow in a report on Tuesday, September 2nd. They issued an "overweight" rating and a $36.00 target price for the company. Morgan Stanley started coverage on shares of Heartflow in a report on Tuesday, September 2nd. They set an "equal weight" rating and a $35.00 price objective for the company. Zacks Research upgraded shares of Heartflow to a "hold" rating in a research note on Wednesday. Canaccord Genuity Group began coverage on shares of Heartflow in a research note on Tuesday, September 2nd. They issued a "buy" rating and a $35.00 target price for the company. Finally, Piper Sandler initiated coverage on shares of Heartflow in a research note on Tuesday, September 2nd. They set an "overweight" rating and a $38.00 price objective for the company.

Heartflow Stock Performance

HTFL traded down $3.01 during trading on Tuesday, hitting $31.07. 442,043 shares of the company's stock were exchanged, compared to its average volume of 878,154. Heartflow has a fifty-two week low of $26.56 and a fifty-two week high of $36.68.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.